Business
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnershipsSAN DIEGO, CA / ACCESSWIRE / March 14, 2023 /
About this update from Ainos, Inc.
[{"type":"text","content":"Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnershipsSAN DIEGO, CA / ACCESSWIRE / March 14, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (\"Ainos\", or the \"Company\"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has signed a Memorandum of Understanding (\"MoU\") with Merdury Biopharmaceutical Corp., a Taipei Exchange Emerging Stock Board listed company (TPEx: Code 6932) (\"Merdury\"), to jointly explore and develop a strategic business relationship.The MoU is an important component of Ainos' strategy to advance commercialization of its VELDONA® formulation. Under the agreement, Ainos and Merdury (collectively, the \"Parties\") will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's VELDONA® drug candidate for treatment of oral warts in HIV-seropositive patients. The Parties will also explore Ainos' potential licensing of Merdury's new drug development platform technology, and cooperate to identify other partners to participate in the authorization and sales of Ainos' candidate drugs. At the same time, the Parties will evaluate Merdury's capacity to assist Ainos in the development of new manufacturing processes, or other possibilities for drugs required or desired by the Company.Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, \"We are pleased to sign this MoU and begin exploring a potential strategic partnership with Merdury. We look forward to building a successful relationship that delivers sustainable value for our shareholders.\"About Ainos, Inc.Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs.About Merdury Biopharmaceutical Corp.Merdury Pharmaceutical developed a p...